Literature DB >> 32960392

Oncologic Reappraisal of Bile Duct Resection for Middle-Third Cholangiocarcinoma.

Kosuke Jikei1, Tomoki Ebata2, Takashi Mizuno1, Takanori Kyokane3, Hideo Matsubara4, Shinya Yokoyama5, Kenji Kato6, Kiyoshi Suzumura7, Mizuo Hashimoto8, Satoru Kawai9, Masato Nagino1.   

Abstract

BACKGROUND: Although bile duct resection (BDR) in addition to pancreaticoduodenectomy (PD) is considered a surgical approach in patients with middle-third cholangiocarcinoma (MCC), available prognostic information after BDR remains very limited. The aim of this study was to reappraise BDR from the viewpoint of surgical oncology.
METHODS: Patients who underwent BDR or PD for MCC between 2001 and 2010 at 32 Japanese hospitals were included. Clinicopathological factors were retrospectively compared according to surgical procedure to identify a subset cohort who benefited most from BDR.
RESULTS: During the study, 92 patients underwent BDR (n = 38) or PD (n = 54). BDR was characterized by a shorter operation time, less blood loss, less frequent complications, and lower mortality, than PD. The incidence of positive surgical margins was 26.3% versus 5.6% (P = 0.007). The survival rate after BDR was significantly worse than that after PD: 38.8% versus 54.8% at 5 years (P = 0.035), and BDR was independently associated with deteriorated survival [hazard ratio (HR), 1.76; P = 0.023] by multivariable analysis. In the BDR group, tumor length < 15 mm (HR, 3.38; P = 0.017) and ductal margin length ≥ 10 mm (HR, 2.54; P = 0.018) were independent positive prognostic factors. Stratified by these two favorable factors, the 5-year survival rate was 63.0% in patients with 1/2 factors and 6.7% in those with 0 factors (P < 0.001).
CONCLUSION: In patients with MCC, BDR provided a better short-term and a worse long-term outcome than PD. However, patient selection using tumor length and ductal margin length may allow a favorable survival probability even after BDR.

Entities:  

Mesh:

Year:  2020        PMID: 32960392     DOI: 10.1245/s10434-020-09157-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Aggressive behavior of anaplastic undifferentiated carcinoma arising from the hilar bile duct.

Authors:  Masayuki Akita; Eri Maeda; Ryo Ishida; Tatsuya Morikawa; Tohru Nishimura; Koichiro Abe; Akihito Kozuki; Tomohiro Tanaka; Yukihiro Imai; Kunihiko Kaneda
Journal:  Surg Case Rep       Date:  2022-01-17

2.  The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients.

Authors:  Matthew Parsons; Shane Lloyd; Skyler Johnson; Courtney Scaife; Heloisa Soares; Rebecca Kim; Robin Kim; Ignacio Garrido-Laguna; Randa Tao
Journal:  J Gastrointest Cancer       Date:  2022-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.